Device Trial Radar · NCT01757665
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)
Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
777
Actual
Start
Dec 11, 2012
Primary completion
Aug 2017
Study completion Mar 23, 2026
Sponsor
- Lead sponsor
- Edwards LifesciencesPublic (EW)
- Sponsor type
- Industry
- First posted
- Dec 31, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this trial is to confirm that the modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.
Conditions
- Aortic Stenosis
- Mitral Stenosis
- Aortic Valve Insufficiency
- Mitral Valve Insufficiency
- Heart Failure
Interventions
Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000MDevice
Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjects With Structural Valve DeteriorationTime frame: 1 Year Post Implant
Locations
32 sites in 3 countries. Site status is shown where the registry gives one.
Cardiology, P.C.
Birmingham, Alabama
University of Southern California
Los Angeles, California
Sutter Institute for Medical Research
Sacramento, California
29 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.